Index - P/E - EPS (ttm) -1.64 Insider Own 70.83% Shs Outstand 30.06M Perf Week -15.45%
Market Cap 9.67M Forward P/E - EPS next Y -0.58 Insider Trans 0.00% Shs Float 8.78M Perf Month -28.60%
Income -49.02M PEG - EPS next Q -0.23 Inst Own 4.35% Short Float 1.20% Perf Quarter -18.05%
Sales 27.51M P/S 0.35 EPS this Y 52.44% Inst Trans -12.74% Short Ratio 0.14 Perf Half Y -62.39%
Book/sh 0.01 P/B 40.57 EPS next Y 25.64% ROA -62.89% Short Interest 0.11M Perf Year -87.55%
Cash/sh 0.64 P/C 0.50 EPS next 5Y - ROE -125.42% 52W Range 0.30 - 3.01 Perf YTD -19.47%
Dividend Est. - P/FCF - EPS past 5Y -55.07% ROI -78.95% 52W High -89.33% Beta 1.98
Dividend TTM - Quick Ratio 3.22 Sales past 5Y 63.37% Gross Margin 53.39% 52W Low 7.21% ATR (14) 0.05
Dividend Ex-Date - Current Ratio 3.71 EPS Y/Y TTM 0.32% Oper. Margin -127.78% RSI (14) 32.75 Volatility 20.52% 12.01%
Employees 147 Debt/Eq 1.16 Sales Y/Y TTM 0.27% Profit Margin -178.21% Recom 1.67 Target Price 4.00
Option/Short Yes / Yes LT Debt/Eq 1.10 EPS Q/Q -121.26% Payout - Rel Volume 0.17 Prev Close 0.32
Sales Surprise -0.33% EPS Surprise -154.17% Sales Q/Q -26.32% Earnings Mar 28 AMC Avg Volume 758.16K Price 0.32
SMA20 -20.84% SMA50 -28.93% SMA200 -57.17% Trades
Volume 127,758 Change -0.68%
Apr-18-24 09:00AM
Mar-28-24 11:53PM
04:25PM
(Associated Press Finance)
04:05PM
Feb-26-24 09:15AM
08:44AM
Loading…
Feb-23-24 08:44AM
Nov-13-23 05:32PM
(Associated Press Finance) -5.27%
04:22PM
Nov-07-23 09:00AM
Nov-03-23 12:00PM
Sep-28-23 03:48PM
Aug-29-23 04:05PM
Aug-10-23 04:51PM
(Associated Press Finance)
04:05PM
Aug-03-23 05:00PM
09:05AM
Loading…
Jun-08-23 09:05AM
Jun-06-23 03:00AM
Jun-05-23 05:30PM
May-31-23 05:29PM
May-23-23 09:00AM
May-22-23 12:00PM
May-18-23 10:00AM
May-15-23 09:00AM
May-13-23 08:05AM
May-12-23 04:17PM
May-11-23 05:25PM
04:22PM
04:05PM
Apr-27-23 04:05PM
Apr-17-23 07:50AM
06:47AM
Loading…
06:47AM
Mar-31-23 09:00AM
Mar-28-23 04:59AM
Mar-25-23 08:21AM
Mar-21-23 05:25PM
04:05PM
Mar-16-23 06:00AM
Mar-14-23 06:00AM
Mar-09-23 04:30PM
Feb-27-23 09:00AM
Feb-16-23 09:00AM
Jan-09-23 09:00AM
Telesis Bio, Inc. engages in the provision of automated multi-omic and synthetic biology solutions. The firm also focuses on providing applications to enable researchers to rapidly, accurately, and reproducibly build or write synthetic DNA and mRNA and short oligonucleotides such as CRISPR guides that are ready to use in many downstream synthetic biology enabled markets. The company was founded by Daniel G. Gibson and J. Craig Venter on March 24, 2011 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Nelson Todd Robert President & CEO May 04 '23 Sale 2.83 2,575 7,277 136,072 May 08 08:11 PM Gibson Daniel Glenn Chief Technology Officer May 04 '23 Sale 2.83 1,190 3,363 102,083 May 08 08:09 PM Cutler Rob Chief Legal Officer May 04 '23 Sale 2.83 1,174 3,318 25,468 May 08 08:06 PM
Index RUT P/E - EPS (ttm) -5.42 Insider Own 2.33% Shs Outstand 96.44M Perf Week -1.53%
Market Cap 2.04B Forward P/E - EPS next Y -5.64 Insider Trans -2.33% Shs Float 94.19M Perf Month -21.10%
Income -481.19M PEG - EPS next Q -1.38 Inst Own 88.42% Short Float 15.49% Perf Quarter -15.52%
Sales 36.27M P/S 56.29 EPS this Y -2.45% Inst Trans -0.30% Short Ratio 9.47 Perf Half Y -19.57%
Book/sh 11.29 P/B 1.87 EPS next Y -1.53% ROA -34.11% Short Interest 14.59M Perf Year -42.02%
Cash/sh 9.46 P/C 2.24 EPS next 5Y 30.00% ROE -42.10% 52W Range 20.78 - 47.48 Perf YTD -30.57%
Dividend Est. - P/FCF - EPS past 5Y -22.30% ROI -41.96% 52W High -55.41% Beta 1.85
Dividend TTM - Quick Ratio 8.67 Sales past 5Y 12.09% Gross Margin 75.26% 52W Low 1.88% ATR (14) 1.20
Dividend Ex-Date - Current Ratio 8.67 EPS Y/Y TTM 12.31% Oper. Margin -1420.51% RSI (14) 28.38 Volatility 4.65% 4.49%
Employees 526 Debt/Eq 0.11 Sales Y/Y TTM -30.40% Profit Margin -1326.51% Recom 1.54 Target Price 69.57
Option/Short Yes / Yes LT Debt/Eq 0.09 EPS Q/Q -4.64% Payout - Rel Volume 0.55 Prev Close 21.53
Sales Surprise -115.04% EPS Surprise -1.49% Sales Q/Q -114.12% Earnings Feb 22 BMO Avg Volume 1.54M Price 21.17
SMA20 -12.87% SMA50 -21.51% SMA200 -31.65% Trades
Volume 859,470 Change -1.67%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-23-24 Downgrade Goldman
Buy → Neutral
$136 → $32
Feb-15-24 Initiated Wolfe Research
Peer Perform
Apr-13-23 Initiated Canaccord Genuity
Buy
$66
Mar-21-23 Initiated Bernstein
Outperform
$54
Mar-14-23 Upgrade BMO Capital Markets
Market Perform → Outperform
$54 → $57
Feb-01-23 Initiated Cantor Fitzgerald
Overweight
$67
Jan-24-23 Upgrade Citigroup
Sell → Neutral
$48 → $39
Jan-19-23 Downgrade JMP Securities
Mkt Outperform → Mkt Perform
Oct-11-22 Initiated Morgan Stanley
Overweight
$84
Sep-21-22 Initiated JP Morgan
Overweight
$85
Sep-01-22 Initiated Citigroup
Sell
$50
Jun-17-22 Initiated BMO Capital Markets
Market Perform
$54
Jun-16-22 Initiated BofA Securities
Buy
$70
Apr-28-22 Initiated Credit Suisse
Outperform
$100
Feb-18-22 Initiated William Blair
Outperform
$144
Feb-07-22 Upgrade Oppenheimer
Perform → Outperform
$145 → $150
Jan-31-22 Initiated Cowen
Outperform
Jan-07-22 Initiated Piper Sandler
Overweight
$171
Oct-05-21 Initiated Guggenheim
Buy
$170
Sep-24-21 Initiated Stifel
Buy
$173
Show Previous Ratings
Apr-14-24 05:55AM
Apr-12-24 04:50AM
Apr-09-24 04:50AM
Mar-28-24 05:55AM
Mar-21-24 05:29PM
04:19PM
Loading…
04:19PM
Mar-19-24 01:06PM
Mar-18-24 07:30AM
Mar-09-24 09:45AM
Mar-06-24 10:35AM
Mar-01-24 01:43PM
Feb-29-24 05:50AM
Feb-28-24 09:30AM
Feb-27-24 11:55AM
09:35AM
12:22PM
Loading…
Feb-23-24 12:22PM
11:12AM
09:55AM
Feb-22-24 10:53PM
(Thomson Reuters StreetEvents)
08:12AM
07:30AM
Feb-20-24 05:02AM
Feb-17-24 01:59AM
Feb-15-24 10:00AM
07:30AM
06:20AM
Feb-14-24 07:30AM
Feb-13-24 06:05AM
Feb-10-24 05:09PM
Feb-08-24 01:15PM
11:50AM
Loading…
Feb-07-24 11:50AM
Feb-05-24 05:25AM
Jan-31-24 05:00PM
12:28PM
Jan-30-24 05:10AM
Jan-29-24 09:35AM
Jan-27-24 01:25PM
08:55AM
Jan-24-24 07:00AM
Jan-22-24 05:41PM
Jan-21-24 08:00AM
Jan-18-24 11:50AM
Jan-13-24 06:05AM
Jan-12-24 08:44AM
Jan-08-24 07:45AM
05:52AM
Jan-05-24 10:04AM
Jan-04-24 04:01PM
12:47PM
Dec-31-23 08:45AM
Dec-27-23 06:41PM
Dec-16-23 05:00AM
Dec-13-23 05:20AM
Dec-12-23 06:00AM
Dec-10-23 11:57AM
Nov-28-23 05:30AM
Nov-24-23 07:00AM
(The Wall Street Journal)
Nov-15-23 11:07AM
Nov-14-23 07:30AM
Nov-10-23 05:38PM
06:30AM
Nov-09-23 04:06PM
03:37PM
08:29AM
07:30AM
Nov-06-23 08:02AM
(Investor's Business Daily)
Nov-02-23 07:00AM
06:45AM
Oct-30-23 03:46PM
10:00AM
Oct-28-23 07:30AM
Oct-26-23 10:02AM
07:30AM
Oct-23-23 09:40AM
08:45AM
Oct-21-23 05:00AM
Oct-19-23 11:46AM
Oct-18-23 04:10PM
(Investor's Business Daily)
07:00AM
Oct-16-23 12:39PM
10:43AM
Oct-14-23 12:20PM
Oct-13-23 08:38AM
Oct-12-23 08:57AM
Oct-10-23 02:00PM
10:07AM
Oct-06-23 04:59AM
Oct-05-23 09:15AM
Oct-04-23 09:27AM
Oct-03-23 10:07AM
07:58AM
07:08AM
07:00AM
Sep-23-23 09:45AM
Sep-10-23 08:15AM
Sep-09-23 03:59PM
Sep-06-23 02:00PM
Sep-05-23 09:52AM
Sep-01-23 10:00AM
Aug-31-23 05:42AM
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
BASTA JAMES EVP, General Counsel Mar 04 '24 Sale 32.99 2,297 75,778 81,571 Mar 05 04:10 PM Clark Eliana EVP, Chief Technical Officer Mar 04 '24 Sale 32.99 605 19,959 71,470 Mar 05 04:10 PM Sepp-Lorenzino Laura EVP, Chief Scientific Officer Jan 08 '24 Sale 28.87 2,275 65,682 43,927 Jan 10 04:15 PM LEONARD JOHN M President and CEO Jan 03 '24 Sale 29.46 19,223 566,310 846,486 Jan 05 04:51 PM Lebwohl David EVP, Chief Medical Officer Jan 03 '24 Sale 29.46 5,843 172,135 54,372 Jan 05 04:50 PM Sepp-Lorenzino Laura EVP, Chief Scientific Officer Jan 03 '24 Sale 29.46 5,532 162,973 46,202 Jan 05 04:50 PM Goddard Glenn EVP, Chief Financial Officer Jan 03 '24 Sale 29.46 5,365 158,053 40,585 Jan 05 04:49 PM Clark Eliana EVP, Chief Technical Officer Jan 03 '24 Sale 29.50 4,608 135,954 40,845 Jan 05 04:44 PM Hicks Derek EVP, Chief Business Officer Jan 03 '24 Sale 29.46 3,877 114,216 36,987 Jan 05 04:46 PM BASTA JAMES EVP, General Counsel Jan 03 '24 Sale 29.46 3,805 112,095 51,474 Jan 05 04:45 PM Bhanji Muna Director Oct 31 '23 Sale 23.90 265 6,334 11,996 Nov 02 04:42 PM Bhanji Muna Director Jul 31 '23 Sale 42.33 265 11,217 12,261 Aug 02 05:19 PM Bhanji Muna Director Jul 06 '23 Sale 39.30 1,867 73,373 12,526 Jul 10 05:21 PM Clark Eliana EVP, Chief Technical Officer Jul 03 '23 Sale 40.51 360 14,584 45,146 Jul 06 03:34 PM Clark Eliana EVP, Chief Technical Officer Jun 20 '23 Option Exercise 12.27 5,000 61,350 50,146 Jun 22 05:52 PM Clark Eliana EVP, Chief Technical Officer Jun 20 '23 Sale 45.00 5,000 225,000 45,146 Jun 22 05:52 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
